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from medical care interventions than from primary pre-
ventive policy measures. Gender and ethnic differences in
amenable mortality were also observed, calling attention
to issues of socioeconomic equities to be addressed in the
financing and delivery of health care.
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OBJECTIVE: To perform a policy impact analysis of
pharmaceutical cost containment strategies implemented
by a third party payer (ministry of health (MOH)), in the
province of Alberta, Canada, during the 1990s. METH-
ODS: A retrospective, pre-post policy intervention regres-
sion-based time trend analysis of seniors’ prescription
drug expenditures between July 1992 and September
1999 was used for the evaluation. All seniors (aged 65
and older) in Alberta are eligible for publically subsidized
prescription drug coverage. The policies included the in-
troduction of least cost alternative (LCA) pricing for in-
terchangeable drug products, pharmacy reimbursement
changes, an increase in the co-payment rate by seniors
from 20% to 30%, and the introduction of a maximum
co-payment cap of $25 per prescription. Policies were
primarily evaluated from the societal perspective, and
economic re-distributional consequences were also exam-
ined. RESULTS: Total drug expenditures for 1999 were
approximately Can$230 million (M) for the 300,000 eli-
gible beneficiaries (seniors) in Alberta. The LCA and
pharmacy reimbursement policies reduced overall soci-
etal costs by approximately 10%, or Can$21.3M in 1999
(95% CI 7.4M–34.5M); the ministry saved Can$18.1M
(95% CI 7.0M–29.2M) and out-of-pocket costs to se-
niors were reduced Can$3.6M (95% CI 0.2M–7.0M). An
increase in the coinsurance rate and introduction of a
maximum cap did not significantly decrease total drug
expenditures, but the MOH realized significant savings
of Can$18.0M (95% CI 4.6M–31.3M) while drug costs
to seniors increased by Can$10.2M (95% CI 6.0M–14.3M)
in 1999. CONCLUSION: The LCA and pharmacy reim-
bursement restructuring policies were effective in signifi-
cantly decreasing overall drug costs to society. The in-
crease in the co-insurance rate and introduction of a cap
resulted in significant savings for the ministry but was
achieved by shifting costs to seniors, raising issues of ac-
cess and equity.
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A number of countries have developed pharmacoeco-
nomic (PE) guidelines for three objectives: regulatory re-
quirements, standardization of methods, implementation
of Good PE Practice. At least 18 countries have issued
such guidelines. OBJECTIVES: To compare and contrast
existing guidelines for their usefulness and relevance for
the practising health economist. Specifically, we aimed to
highlight areas of agreement and dissent, and identify is-
sues with practical implications in the different countries.
METHODS: Existing documents were reviewed, ana-
lyzed, and a comparison undertaken. The following top-
ics were considered when reviewing the documents: (1)
objective (pricing and reimbursement, formulary inscrip-
tion, state of the art), (2) degree of precision and pre-
scription, (3) international consensus and (4) divergence
(type of analyses, comparator, perspective, costing and
implementation). Within each topic, issues addressed by
the countries have been identified, and any recommenda-
tions promulgated have been compared. RESULTS: Ac-
cording to the degree of guideline prescription, three
groups of countries can be identified: “soft” guidelines
including countries such as Finland and Belgium; “mod-
erate” guidelines such as Canada and Denmark and
“strict” guidelines such as Australia and the Netherlands.
For a number of issues, recommendations are consistent
between the countries. For example, all national docu-
ments recommend that a societal perspective should be
adopted and economic data should be described in both
natural and monetary units. By contrast, there is a lack of
consensus concerning costing. CONCLUSIONS: This work
indicates that collaboration across countries and between
sponsors, researchers and decision-makers is essential to
reach an optimal degree of agreement and to perform
convincing and useful studies. When designing an inter-
national PE study, it is essential to take into account local
guideline requirements as they may lead to practical im-
plications.
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